Hemolytic-uremic syndrome (HUS) is a disease that has been described as a triad of hemolytic anemia, thrombocytopenia and renal impairment. There are two types of HUS, typical and atypical. HUS remains a leading cause of acute renal injury in adults. The annual incidence of HUS in the United States is approximately 2.2 cases per 100,000 population, as well as in Europe [11].

HUS and thrombotic thrombocytopenic purpura (TTP) are the two main variants of thrombotic microangiopathies (TMA) and related disorders [10]. HUS remains a leading cause of acute kidney injury in North American children and is increasingly recognized as a cause of kidney dysfunction in adults. The annual incidence of HUS in the United States is approximately 2.2 cases per 100,000 population, as well as in Europe [11].

There was no study done in Oman and very limited from the whole region about HUS. Hence, the objective of our study is to evaluate the demographic features, clinical characteristics, management and outcome of HUS in Omani population presented in the main tertiary hospital.

**Methodology:** This is a retrospective descriptive study evaluating all cases of Hemolytic Uremic Syndrome (HUS) that have been admitted at Royal Hospital (RH) Oman in the period between 2006 and 2015.

**Results:** Thirty six patients identified. The mean age (SD) of 10.68 (14.07) years. Eighteen (50%) presented with abdominal pain, nausea, vomiting and diarrhea, 9 (25 %) with hypertension, 23 (64 %) with acute kidney injury (AKI), 6 (16.67%) with seizure, 2 (5.56%) with confusion and 1 (2.78%) with cerebrovascular accident (CVA). Twenty-one (58.33 %) diagnosed as typical HUS of which 19 with Shiga toxin producing Escherichia Coli (STEC) HUS and 2 had post Streptococal HUS. Six (16.67%) diagnosed with aHUS, 2 (5.56%) with HELLP, 2 (5.56%) with G6PD, 3 (8.33%) with Auto immune hemolytic anemia (AIHA ), 1 (2.78%) with congenital TTP and 1 (2.78%) with post partum HUS.Twenty three (63.89%) needed renal replacement therapy (RRT), while remaining 13 (36.11%) did not require RRT. Eleven (30.56%) received plasma exchange, 5 (13.89%) received Eculizumab while 2 (5.56%) received plasma infusion and 1 (2.78%) patient received Rituximab. The majority 22 (61.11%) had partial recovery after treatment, 5 (13.89 %) had complete recovery and 3 (8.33%) ended with end stage kidney disease (ESKD) and 1 (2.78%) died from hypertensive crises.

**Conclusion:** The study results showed that HUS populations were mostly due to Shiga toxin producing Escherichia Coli (STEC). It showed that HUS population were young, mostly male and only 25% have known medical comorbidities at time of presentation. Also, the majority presented with AKI requiring dialysis, of which PD was main stay of therapy. The duration of RRT and recovery time was almost a month period.

**Abstract**

**Introduction:** Hemolytic-uremic syndrome (HUS) is a disease that has been initially identified in 1955 and described as a triad of sudden drop of hemoglobin (hemolytic anemia), thrombocytopenia and kidney dysfunction [1, 2]. It affects predominantly, but not exclusively, children [3-6]. There are two types of HUS. Typical HUS that follows infection like E. coli O157:H7, Shiga toxin and others [3, 4, 6, 7]. Atypical HUS (aHUS) defined as non-Shiga-toxin-HUS that results from dysregulation of the complement alternative pathway and has a less favorable outcome [8, 9].

HUS and thrombotic thrombocytopenic purpura (TTP) are the two main variants of thrombotic microangiopathies (TMA) and related disorders [10]. HUS remains a leading cause of acute kidney injury in North American children and is increasingly recognized as a cause of kidney dysfunction in adults. The annual incidence of HUS in the United States is approximately 2.2 cases per 100,000 population, as well as in Europe [11].

There was no study done in Oman and very limited from the whole region about HUS. Hence, the objective of our study is to evaluate the demographic features, clinical characteristics, management and outcome of HUS in Omani population presented in the main tertiary hospital.

**Methodology:** This is a retrospective descriptive study evaluating all cases of HUS that have been admitted at Royal Hospital (RH) Oman in the period between 2006 and 2015.

**Results:** Thirty six patients identified. The mean age (SD) of 10.68 (14.07) years. Eighteen (50%) presented with abdominal pain, nausea, vomiting and diarrhea, 9 (25 %) with hypertension, 23 (64 %) with acute kidney injury (AKI), 6 (16.67%) with seizure, 2 (5.56%) with confusion and 1 (2.78%) with cerebrovascular accident (CVA). Twenty-one (58.33 %) diagnosed as typical HUS of which 19 with Shiga toxin producing Escherichia Coli (STEC) HUS and 2 had post Streptococal HUS. Six (16.67%) diagnosed with aHUS, 2 (5.56%) with HELLP, 2 (5.56%) with G6PD, 3 (8.33%) with Auto immune hemolytic anemia (AIHA ), 1 (2.78%) with congenital TTP and 1 (2.78%) with post partum HUS.Twenty three (63.89%) needed renal replacement therapy (RRT), while remaining 13 (36.11%) did not require RRT. Eleven (30.56%) received plasma exchange, 5 (13.89%) received Eculizumab while 2 (5.56%) received plasma infusion and 1 (2.78%) patient received Rituximab. The majority 22 (61.11%) had partial recovery after treatment, 5 (13.89 %) had complete recovery and 3 (8.33%) ended with end stage kidney disease (ESKD) and 1 (2.78%) died from hypertensive crises.

**Conclusion:** The study results showed that HUS populations were mostly due to Shiga toxin producing Escherichia Coli (STEC). It showed that HUS population were young, mostly male and only 25% have known medical comorbidities at time of presentation. Also, the majority presented with AKI requiring dialysis, of which PD was main stay of therapy. The duration of RRT and recovery time was almost a month period.
protein (CRP), Erythrocytic Sedimentation Rate (ESR) Bone & liver coagulation profile, renal functions, complements profile, complements function, genetic study, radiological assessment including abdominal Ultrasound were retrieved. Also, various management and outcomes were recorded.

The process of data entry and analysis were always rechecked by two researchers. An epidemiologist was involved throughout the study. This started from the first meeting and conception of the research idea till the end of the study. Quality control data was done as per our institute research guidelines. Statistical analysis was completed using Stata software, Chicago, Ill. USA.

Results
The majority of patients were young with a mean age (SD) of 10.68 (14.07) years. Youngest was 6 months old while the oldest was 46 years old, and 21 (58.33 %) patients were males. Majority were from outside the capital 28 (77.78 %) and the rest from Muscat region 8 (22.22 %).

Most of the patients had no medical co-morbidities but 8 (25%) had the following: 3 (8.33%) were hypertensive (HTN), 2 (5.56%) were known to have chronic kidney disease (CKD), 2 (5.56%) were obese and only 1 (2.78%) was a known dyslipidemic.

Eighteen (50 %) of the patients presented with abdominal pain, nausea, vomiting and diarrhea, 9 (25 %) patients presented with HTN, 23 (64 %) patients presented with acute kidney injury (AKI). Six patients (16.67 %) presented with seizure while 2 (5.56%) had confusion and only 1 (2.78 %) had cerebrovascular accident (CVA).

Various laboratory parameters were done at the time of initial presentation and diagnosis and after receiving the various management therapies, as shown in tables 1 and 2. The tables illustrates the improvement of these laboratory measurement with time.

<table>
<thead>
<tr>
<th>variable</th>
<th>Normal value</th>
<th>mean</th>
<th>Mean2</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb</td>
<td>11.5-15.5 g/dL</td>
<td>7.957 (2.35)</td>
<td>11.9 (1.76)</td>
<td>0.0000</td>
</tr>
<tr>
<td>TLC</td>
<td>2.2-10 10^9/L</td>
<td>15.22 (9.06)</td>
<td>7.13 (2.75)</td>
<td>0.0000</td>
</tr>
<tr>
<td>ANC</td>
<td>1-5 10^9/L</td>
<td>8.99 (7.60)</td>
<td>2.66 (1.71)</td>
<td>0.0001</td>
</tr>
<tr>
<td>LC</td>
<td>1.2-4 10^9/L</td>
<td>4.48 (2.80)</td>
<td>3.50 (1.64)</td>
<td>0.0435</td>
</tr>
<tr>
<td>EC</td>
<td>0.1-0.5 10^9/L</td>
<td>0.25 (0.33)</td>
<td>0.34 (0.29)</td>
<td>0.2119</td>
</tr>
<tr>
<td>MC</td>
<td>0.1-1.3 10^9/L</td>
<td>1.46 (1.08)</td>
<td>0.60 (0.36)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Plt</td>
<td>140-400 10^9/L</td>
<td>95.57 (97.27)</td>
<td>282.56 (89.52)</td>
<td>0</td>
</tr>
<tr>
<td>RC</td>
<td>0.5-3 %</td>
<td>5.26 (4.31)</td>
<td>2.42 (1.75)</td>
<td>0.008</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>&lt;5 mg/L</td>
<td>76.40 (66.54)</td>
<td>14.64 (21.61)</td>
<td>0.0005</td>
</tr>
<tr>
<td>ESR</td>
<td>2-25 mm/h</td>
<td>5.00 (46.87)</td>
<td>43.33 (51.08)</td>
<td>0.4226</td>
</tr>
<tr>
<td>PT</td>
<td>9.8-11.9 s</td>
<td>11.62 (2.13)</td>
<td>10.97 (1.08)</td>
<td>0.1729</td>
</tr>
<tr>
<td>APTT</td>
<td>26.4-38.9 s</td>
<td>38.03 (8.95)</td>
<td>34.13 (4.85)</td>
<td>0.0465</td>
</tr>
<tr>
<td>TT</td>
<td>14.3-17.8 s</td>
<td>16.17 (4.12)</td>
<td>14.40 (2.34)</td>
<td>0.0569</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>1.6-4 g/L</td>
<td>3.35 (3.50)</td>
<td>3.30 (1.20)</td>
<td>0.902</td>
</tr>
<tr>
<td>Calcium</td>
<td>2.1-2.6 mmol/L</td>
<td>2.38 (0.18)</td>
<td>2.47 (0.13)</td>
<td>0.0269</td>
</tr>
<tr>
<td>phosphorus</td>
<td>0.75-1.5 mmol/L</td>
<td>2.02 (0.68)</td>
<td>1.63 (0.24)</td>
<td>0.0019</td>
</tr>
<tr>
<td>Iron</td>
<td>9-30 umol/L</td>
<td>9.08 (4.94)</td>
<td>14.53 (4.83)</td>
<td>0.0657</td>
</tr>
</tbody>
</table>
The blood film showed significant improvement of anemia, thrombocytopenia and reduction of percentage of schistocytes between the time at presentation and after treatment, as shown in table 2.

Twenty-one (58.33 %) patients were diagnosed as typical HUS of which 19 were diagnosed as Shiga toxin producing Escherichia Coli (STEC) HUS, while the remaining 2 had post Streptococcal HUS.

Six (16.67 %) patients were diagnosed as aHUS, 2 (5.56%) patients with HELLP, 2 (5.56 %) with G6PD, 3 (8.33 %) with Autoimmune hemolytic anemia (AIHA ), one (2.78%) with congenital TTP and one (2.78%) was diagnosed as post partum HUS.

Twenty-three (63.89 %) patients needed renal replacement therapy (RRT), while remaining 13 (36.11%) did not require RRT. In the typical HUS, 18 from 21 (86%) patients, aHUS 4 from 6 (67 %) and one patient from 2 (50%) with HELLP.

Sixteen of 23 patients (69.5%) received peritoneal dialysis (PD) (all of them with typical HUS ), while the remaining 7 (30.5 % ) received HD (3 patient with typical HUS, 3 patients with aHUS and one patient with HELLP).

Eleven patients (30.56%) received plasma exchange, 5 (13.89%) patients received Eculizumab while two patients received plasma infusion (5.56%) and one (2.78%) patient received Rituximab.
The mean (SD) of the RRT duration was 33.2 (31.8) days, while the recovery time was 36 (33.7) days.

Five (16.67 %) patients had normal renal function on presentation and remain same through the treatment course, while the majority of the patients, 22 (61.11%) had partial recovery after treatment, 5 (13.89 %) had complete recovery and 3 (8.33%) ended with end stage kidney disease (ESKD) and 1 (2.78%) died from hypertensive crises.

Discussion

This is the first study reporting HUS from Oman. HUS triad, of hemolytic anemia, thrombocytopenia and kidney dysfunction was established, from sudden drop in Hb, decreased platelets and abnormal kidney function as shown in table 1-3. The study results showed that HUS populations were mostly due to Shiga toxin producing Escherichia Coli (STEC). It showed that HUS population were young, mostly male and only 25% have known medical comorbidities at time of presentation. Also, the majority presented with AKI requiring dialysis, of which PD was main stay of therapy. The duration of RRT and recovery time was almost a month period.

Previous studies showed that the average annual incidence for HUS of 0.71 per 100,000 children in Germany while it was 0.7 cases/100,000 and 0.6 cases/100,000 in France and Australia, respectively [3, 12]. The highest HUS incidence worldwide occurs in Argentina, although exact incidence rates are unclear [6, 13, 14]. A relatively lower incidence was reported in Italy (0.2 cases/100,000 children) [5, 15].

Our study results were in concordance with the world-wide pattern of the disease’s young age incidence [1, 3, 7, 16-19], with mean age (SD) 10.68 (14.07) years. We also found that there was relatively higher incidence of the disease in males (58.33 %) which is similar to what was found by other researchers in our region, Saudi Arabia and Kuwait [16] whereas other researchers reported relative predominance of females [18, 20].

In the present study, the total white cell count was very high with a mean (SD) 15.2 (9.1) and neutrophil leukocytosis of 8.99 (7.7) at time of presentation. Researchers noted that the presence of high polymorphonuclear neutrophil counts in patients with HUS indicates a poor prognosis [13, 21-25]. The important role of leukocytes in the pathogenesis of HUS and its endothelial dysfunction leading to HUS was also noted to be of vital role [24-26]. In vitro experiments, STEC binds to leukocytes and is transferred by them to endothelial cells [20, 24, 25]. Accordingly, STEC also has been detected on the surface of circulating leukocytes of patients with HUS [21, 22, 27], and in a murine HUS model, STEC 2 induced neutrophilia and neutrophil activation [28, 29]. Also, in clinical studies, initial leukocytosis has been described as a predictor for development of HUS [13, 23, 26, 30, 31].

AKI is a common manifestation of TMAs, although rarely a severe feature of TTP [2]. Extra renal manifestations are reported in TMAs, with the published data referring primarily to those observed in complement-mediated aHUS and STEC-HUS, although it is not known whether they are a consequence of the TMA, a direct effect of complement activation or shiga toxin, or complications of AKI, such as severe hypertension and uremia [32].

Though majority of our studied patients had no co-morbid conditions, however it is possible that those who had preexisting other medical conditions like HTN, CKD, dyslipidemia and obesity might have contributed to poor outcomes. Gerber et al found that diarrhea was present in 91% of patients [20]. Neurologic symptoms, mainly seizures and stupor were found in 25% of patients. Hypertension during the acute course occurred in 15% of case subjects [20]. In our study we found that 64% of patients had AKI, 50 % with gastrointestinal symptoms, 25% with HTN, 16.67% with seizure, 5.56% with confusion and 2.78% with cerebrovascular accident (CVA).

Studies have shown that the indication for initiating dialysis is variable. In the present study, two third (63.9 %) of patients needed RRT, of which the majority were on PD (69.5%). Most centers in Germany and Austria start dialysis on the day of admission if oliguria or anuria is present. Data from France (53%) [4] and the United States (55%) [18, 33] showed a lower portion of dialyzed patients than in Germany, Austria, and Australia (63%) [2, 8, 15, 20].

Several reports indicate that the duration of dialysis is a predictor for long-term outcome [2, 8, 15, 34, 35]. This study found that the mean duration of RRT was 33.2 SD (31.8) days while the mean time to recovery was 36 SD (33.7) days. These findings are similar to those reported from neighboring countries [16, 19]. However, another study reported a lower mean duration of dialysis of 18 days (range three to 56 days) [36].

While we had a low mortality of 2.78%, which is similar to a Saudi report of 3% mortality rate [36]. Other studies reported rates as high as (6%) in the United Stated [2, 35], followed by Australia (4%) [8, 12], Germany (2%), and France (1.4%) [3].

Our study has few limitations including that is it retrospective, small sample size and possibly not including all cases due to lack of a database registry in Oman. Another problem is poor documentation and lack of continuity within a fragmented network of both public and private providers that also may underestimate the incidence and prevalence of this health problems. However complicated cases usually referred to our center.

Conclusion

It is the first report of HUS from Oman. Our results were in concordance with the world-wide pattern of the disease’s young age incidence and disease presentation and complications with lower mortality rates. It would be prudent to establish a national Oman TMA registry for better capturing of cases and to provide more extensive and accurate data to the health authority for future health care planning.
Acknowledgement

The authors would like to acknowledge the help and support of the Oman Medical Specialty Board, particularly the Research Department.

References


The Epidemiology of Hemolytic Uremic Syndrome: Clinical Presentation, Laboratory Findings, Management and Outcomes


